The scope of the collection of Chinese medicines expanded, and a number of more than 1 billion yuan varieties should be reduced.

Author:Kenji Bureau Time:2022.07.22

Following the Guangdong and Hubei Alliance, other provinces are also rapidly keeping up with Chinese medicine collection.

On July 22, the Notice of the Reporting of the Third Batch of Pharmaceuticals (Special Pharmaceuticals) in Shandong Province "was widely circulated in the pharmaceutical circle. According to the document, the scope of the collection of this collection is a private hospital for all public medical institutions, troops hospitals, and the implementation of medical insurance reimbursement policies.

The Jianzhi Bureau was informed that the special collection of Chinese medicines this time and the varieties of the two major alliances of Hubei and Guangdong have similar things. There are also thrombosis, blood Seyong, ginkgo leaves, etc., which also covers compound thrombosis, healthy stomach eliminates diet, eliminating stomach and digestion. Wait for the varieties that have not been collected before. Internal insiders of the hospital revealed to the Jianzhi Bureau that the varieties of Chinese medicine collection and mining of Shandong Province all belonged to the relatively large clinical dosage in the province.

The deadline for the report of the collection of Chinese medicines in Shandong is July 27. Shandong stipulates that if the number of hospital procurement needs to decrease by more than 20%compared with the actual procurement volume, the reason for submitting the instructions in the system must be submitted.

However, the "Notice" did not disclose the specific collection rules. The industry generally believes that Shandong is likely to be traded in the form of "volume and price adaptation, intelligent matching, transparent and openness" of Hubei and Guangdong. And the winning price of the Hubei and Guangdong Alliance is a good reference.

If this collection can be successful, Shandong will become the first province in the country to carry out special collection of Chinese medicine.

Drawing on the experience of Hubei and Guangdong, the corporate price reduction is becoming more rational

As the collection enters the normalization, the Chinese patent medicine is also difficult to escape and reduce the price.

In January 2022, the Shandong Provincial Medical Insurance Bureau issued a notice that since July 2022, the Provincial Medical Insurance Bureau has established an inter -provincial traditional Chinese medicine (material) alliance Internet trading platform. After one year of trial operation, it has a network transaction. Function of alliance purchases.

This time in Shandong's provinces, Sino -P Chinese -paddish collection, there are many clinical varieties with annual sales exceeding 1 billion yuan.

According to Mine.com data, in 2019, the sales of Blood Saitong and thrombosis nationwide were 6.683 billion yuan and 6.53 billion yuan, respectively. The sales of Bailing Capsules were as high as 3.486 billion yuan. And the stomach -eliminating tablets, ginseng injections, small gold capsules, Shukinning injection, etc. are also clinically sold.

With reference to the data of Hubei and Guangdong, the price reduction of Chinese medicine collection is relatively rational.

The Guangdong Medicine Collection Alliance was selected in the end of the 361 varieties, a decrease of about 21%. The average price of the collection of patent medicines in Hubei Chinese medicines has reached 42.27%. Industry insiders believe that compared with 6 provinces in Guangdong, Hubei Medicine Collection Alliance covers 19 provinces. The greater the attractiveness.

Shandong is the sixth province of drug sales in the country. The annual sales of Chinese medicines exceeds 10 billion yuan, and it has the confidence that organizes the collection alone.

In May of this year, Qiu Bingyu, a first -level inspector of the Shandong Medical Insurance Bureau, previously publicly stated that Shandong will promote the acceleration of provincial pharmaceutical collection. Focusing on Chinese medicine, the third batch of drug collection of drugs in the province is carried out.

After Shandong is the Hubei and Guangdong Alliance, the third organizational provinces are organized. Moreover, Shandong has led 12 provinces including Tianjin, Inner Mongolia, Liaoning, Jilin, Heilongjiang, and Fujian to plan to carry out inter -provincial patent medicine collection. In the future, Hubei, Guangdong, and Shandong will likely appear to have a "three -legged" situation.

These three alliances have basically covered all provinces in the country. The further price reduction of Chinese medicines in the future is the matter of nailing on the board.

Cutting is not the purpose, cut off over -marketing

On July 22, Li Shuchun, deputy director of the Department of Medicine Management Department of the State Medical Insurance Bureau, said that since 2018, 7 batches of national organizational drug collection has been intensively promoted, which covers 294 medicines, most of which are commonly used for common diseases and chronic diseases. The amount accounts for 35%of the procurement of chemicals and biopharmaceuticals in public medical institutions, with an average price reduction of more than 50%.

Chemical drugs and biopharmaceuticals have entered the national collection, and Chinese medicines have been carried out in the form of provincial and inter -provincial alliances. This has been included in the key work of the year.

Compared with chemicals and biopharmaceuticals, the quality standards of proprietary Chinese medicines are difficult to be clear and clear. It is difficult to develop consistent evaluation due to factors such as raw materials, production processes, administration methods, packaging and storage. Therefore, in Hubei and Guangdong's two collection reports, the comprehensive criteria of price competition and technical scores have been increased.

The purpose of concentrated band procurement of Chinese medicines is not to flatten the price, nor is it to flatten the cost and profit of the manufacturer, but to strive to remove or reduce the virtual high part of the factory price and terminal prices. It is necessary to change the unreasonable sales model, so that the selected products do not need to be over -marketing, and collectively go to "fat".

Although the rules of the Sino -Academy Collection of Medicine Collection of Hubei, Guangdong, and Shandong Province have different rules, the rules of provincial collection of collection are more flexible and complicated compared with the national ministry. Dynamic comprehensive management and control measures such as balance distribution, incremental management, peak -cutting, low -cost resurrection, etc., making it easier for participating companies to operate.

It is undeniable that the collection has changed the competition rules of the Chinese medicine market, and the company's business model is impact.

The industry generally believes that, whether or not they enter the collection, enterprises must return to the essence of drugs, pay attention to innovative research and development, and strive to achieve a more stable industrial system of R & D, production, and sales in order to obtain better brand reputation.